Dermatology

Acne is a multifactorial disease of the pilosebaceous unit in the skin. Four contributing pathogenic factors need to be elucidated and include excess sebum production, follicular hyperkeratinization, colonization of the pilosebaceous unit by Propionibacterium acnes.

Update on Targeted alkali thermolysis (TAT) technology (Brella™ 3-miniute SweatControl Patch™), Retifanlimab-dlwr for IV infusion (Zynyz™), Spesolimab IV for IV infusion (Spevigo®) and CRISPR-based therapy (NTLA-2002).

We review the various controversies surrounding sunscreen use.

Cyanoacrylates are surgical adhesives that provide another option for wound closure. There are a number of surgical adhesives either currently available or under development. The presently available butylcyanoacrylates and octylcyanoacrylates are reviewed.

Cutaneous T-cell lymphomas are rare, distinct forms of non-Hodgkin’s lymphomas, of which, mycosis fungoides and Sézary syndrome are two of the most common forms. This article focuses on a multi-disciplinary approach to workup, diagnosis, and treatment of these conditions.

The latest drug & device update covers: Trifarotene 0.005% cream (Aklief®, Galderma), Afamelanotide implant (Scenesse®, Clinuvel Pharmaceuticals), Rituximab for IV use (Rituxan®, Genentech), Jynneos™ (Bavarian Nordic), Aczone® (Almirall) and Juvéderm Voluma® XC (Allergan)

Update on Bilastine tablet (Blexten™), Ixekizumab SC injection (Talz®), Wound care gel (Lasercyn™ gel), Ceftaroline fosamil (Teflaro®), Nivolumab + ipilimumab (Opdivo® + Yervoy®), PDT for actinic keratosis (Ameluz® gel + BF-RhodoLED®)

This update covers: Guselkumab SC use (Tremfya®), Adalimumab-fkjp SC use (Hulio®), Collagenase clostridium histolyticum-aaes SC use (Qwo™), Protein replacement therapy for XLHED (ER-004), Pembrolizumab IV use (Keytruda®), Minocycline 1.5% foam (Zilxi™), Microbiome-based non-aqueous ointment (ATR-12), Dupilumab SC use (Dupixent®) and Selumetinib capsules (Koselugo™)

Latest drug update covers Pembrolizumab for IV injection (Keytruda®, Merck & Co.), Guselkumab for SC injection (Tremfya®, MorphoSys/Janssen), Dupilumub for SC injection (Dupixent®, Regeneron), and Risankizumab for SC injection (Skyrizi™, AbbVie).

Device-based therapies are promising alternatives for the treatment of onychomycosis because they can mitigate some of the negative factors associated with treatment failure. This article reviews the case for laser and light based therapies, for the treatment of nail fungus.

Dermatosis papulosa nigra is a benign skin lesion found most frequently on the face of patients with skin of color. This article compares treatment modalities for DPN.

Ciclopirox nail lacquer 8% (Penlac, Aventis Pharma) was approved by the US FDA in December 1999, as a component of a comprehensive management program, for use in immunocompetent patients who have mild to moderate onychomycosis of the fingers and toes without lunula involvement due to Trichophyton rubrum.

Chronic pruritus remains a difficult condition to treat with many non-specific therapeutic options. Recent scientific discoveries have elucidated the physiology associated with pruritus.

Updates on: Cetirizine HCl Zyrtec®Pimecrolimus Elidel® Cream Imiquimod Aldara® Cream Valacyclovir HCl Valtrex®

Update on Dabrafenib mesilate capsule (Tafinlar®), Trametinib dimethyl sulfoxide tablet (Mekinist™), and Vismodegib capsule (Erivedge®)

An overview and update of diagnostics and devices introduced in 2011: HPV RNA detection kit APTIMA® HPV Assay, HPV DNA detection kit cobas® HPV Test cobas® 4800 System, Microwave-based device (miraDry®) for hyperhydrosis and many more drugs and devices are covered.

Tobacco smoking is a serious and preventable health hazard that can cause or exacerbate a number of diseases and shorten life expectancy. This article delves into the role of smoking as an etiologic factor in the development of skin disease.

The ichthyoses are a heterogeneous group of inherited scaling skin disorders that can also affect other organs. Management should be directed at both the skin and other sites. Skin therapy is not specific at this time, although new products may offer more directed therapy in the future.

Adatosil® is a viscous silicone oil which was granted FDA approval in 1994. This designation removes the legal obstacles to usage for soft tissue augmentation. However, physicians are advised to exercise discretion when using this product.

Awareness of the molecular mechanisms of antibiotic resistance among bacteria is necessary to understand the etiology of antibiotic resistance in dermatology at the most basic level.

The elderly in North America is the fastest growing segment of the population and their most common skin complaint is pruritus. This article outlines the therapeutic challenges with this population.

There is no ideal filler, nor will there be a single product that can satisfy all requirements. However, RESTYLANE®, a non-animal, stabilized hyaluronic acid (NASHA, Medicis), is a very versatile augmenting agent. It has been in clinical use for 8 years and experience has shown it to be close to the ideal filler in many respects.

Update on (Beteflam™), Human papillomavirus (HPV) 9-valent vaccine, recombinant (Gardasil®9), (Imlygic®), Pembrolizumab IV injection (Keytruda®), Adalimumab SC injection (Humira®), Secukinumab SC injection (Cosentyx®), Ustekinumab SC injection (Stelara®), and Nivolumab + ipilimumab (Opdivo® + Yervoy®).

The discussed cases reflect the panels’ real-world clinical experience with crisaborole for the treatment of patients with AD and the off-label treatment of irritant dermatitis.

Update on: Mupirocin calcium cream 2% Bactroban Cream® Butenafine cream Mentax®Becaplermin gel 0.01% Regranex®Finasteride 1mg tablets Propecia®Minoxidil 5% Rogaine Extra Strength for Men® Dermagraft® Graftskin® (apligraf) UV light as carcinogen

Crisaborole provides a novel and safe treatment option for mild-to-moderate AD.

Localized scleroderma, or morphea, is a chronic disease that causes a thickening and induration of the skin. For plaque type morphea, the treatments include super-potent corticosteroids and calcipotriol. For the more generalized forms, as well as the linear forms, UVA is currently the best therapeutic modality.

Update on Brimonidine tartrate 0.33% topical gel (Mirvaso®), Mechlorethamine gel (Valchlor™), OnabotulinumtoxinA for injection (Botox® Cosmetic), Ustekinumab (Stelara®), Certolizumab pegol (Cimzia®), Infliximab (Inflectra™), Efinaconazole 10% topical solution (Jublia®)

Dermatology supplements, often marketed as “skin, hair, and nail” supplements, are becoming increasingly popular. However, many consumers lack an understanding of the science of dietary supplements or the specifics of the supplement industry.

Update on Autologous cell therapy dermal filler [laVív® (azficel-T)], 5-fluorouracil cream 0.5% + Salicylic acid 10% (Actikerall®), Belimumab (Benlysta®), Ipilimumab (Yervoy™).

Lasers and intense pulsed light sources are frequently used for the treatment of pigmented lesions, and the appropriate selection of devices for different lesions is vital to achieving satisfactory clinical outcomes. In the removal of melanocytic nevi, a combined approach with a long-pulse pigmented laser and a Q-switched laser is particularly applicable.

Onychomycosis is a common disease, and there are a number of factors that may affect the duration and dosage of treatment including the type of onychomycosis, the area and thickness of nail involvement, the age of the patient, and the location of the digit that is affected.

Vitiligo is an acquired skin disorder caused by the disappearance of pigment cells from the epidermis, and results in well defined white patches that are often symmetrically distributed. The lack of melanin pigment makes the lesional skin more sensitive to sunburn.

Update on Calcipotriene/Betamethasone Dipropionate OintmentTaclonex® Warner Chilcott/LEO Pharma, Etanercept Enbrel® Amgen/Wyeth Pharmaceuticals, and drug news about Updated Labeling, Dear Doctor Letter and Cleansing Agents.

Nail fungus, left untreated, the infection can spread to other nails and potentially cause further complications. This article reviews efinaconazole 10% as a topical monotherapy. Clinical trial data, mechanism of action, and future treatments are discussed.

Discover advancements in oral isotretinoin formulations, including micronized isotretinoin, improving bioavailability and reducing food dependency for optimal acne treatment outcomes.

Rituximab is an anti-CD20 monoclonal antibody with considerable potential in dermatology due to an increase in off-label indications. Off-label use of rituximab, indications, side-effects, and dosing are some of the topics discussed.

Update on Drugs & Devices March and April 2018: Hydrogen peroxide topical solution Eskata™, Mepolizumab for SC injection Nucala® GSK, Brentuximab vedotin for IV use Adcetris®, CoolSculpting®, (PDF) patch DeScribe® PFD Patch, Adhesive patch for melanoma detection Pigmented Lesions Assay (PLA)

A variety of new skin treatments introduced in 2019.

The use of nonabsorbable sutures for lifting lax, aging skin is an increasingly popular option for cosmetic surgeons. Contour Threads™ (Surgical Specialties Corp.) are novel modified polypropylene sutures recently approved for this purpose by the US FDA.